Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
18.07
-0.39 (-2.11%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Amneal Pharmaceuticals Employees
Amneal Pharmaceuticals had 8,700 employees as of December 31, 2025. The number of employees increased by 400 or 4.82% compared to the previous year.
Employees
8,700
Change (1Y)
400
Growth (1Y)
4.82%
Revenue / Employee
$358,339
Profits / Employee
$18,088
Market Cap
5.76B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8,700 | 400 | 4.82% |
| Dec 31, 2024 | 8,300 | 450 | 5.73% |
| Dec 31, 2023 | 7,850 | 250 | 3.29% |
| Dec 31, 2022 | 7,600 | 600 | 8.57% |
| Dec 31, 2021 | 7,000 | 1,000 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Dr. Reddy's Laboratories | 27,527 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
| Lantheus Holdings | 1,193 |
| Indivior Pharmaceuticals | 838 |
| Supernus Pharmaceuticals | 778 |
| Kiniksa Pharmaceuticals International, | 366 |
AMRX News
- 2 days ago - Amneal Pharmaceuticals price target raised to $25 from $23 at UBS - TheFly
- 3 days ago - Amneal Pharmaceuticals price target raised to $25 from $23 at UBS - TheFly
- 3 days ago - Amneal Pharmaceuticals price target raised to $25 from $23 at UBS - TheFly
- 6 days ago - Amneal Pharmaceuticals Transcript: EGM 2026 - Transcripts
- 6 days ago - Amneal Pharmaceuticals price target raised to $21 from $19 at Goldman Sachs - TheFly
- 7 days ago - Amneal Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 7 days ago - Amneal Pharmaceuticals Earnings release: Q2 2026 - Filings
- 7 days ago - Amneal Pharmaceuticals Slides: Q2 2026 - Filings